Gapping up
In reaction to strong earnings/guidance: N/A
M&A news:
In reaction to strong earnings/guidance: N/A
M&A news:
- NVDQ +92% (to be acquired by Stryker (SYK) for $11.75/share)
- RICE +28% (Rice Energy and EQT (EQT) acquisition confirmed for total consideration of approximately $6.7 billion)
Select Tech names showing strength:
- FNSR +1.5%, AMD +1.4%, MU +1.3%, MOMO +1.3%, NFLX +1.1%, NVDA+1%, AMZN +0.9%, FB +0.9%, MSFT +0.8%, TSLA +0.8%
Other news:
- CLVS +44% (reports data from Phase 3 ARIEL3 study achieved primary endpoint; plans to submit NDA in next 4 months)
- RIGL +13.2% (FDA has accepted the New Drug Application for TAVALISSE)
- WKHS +4.7% (unveiled its Surefly helicopter concept at the Paris Air Show (Static display B10) and released specifications. The company is now accepting pre-orders for SureFly)
- JD +3.5% (issued an update on its Anniversary Sales)
- HII +3.2% (confirms it has been awarded a $3 billion contract for the detail design and construction of the amphibious assault ship Bougainville)
- VRX +3.2% (announces that its Board has elected John Paulson to serve as a director, effective June 14)
- ADMP +2.9% (continued strength following last week's move higher)
- AAOI +2.9% (continued strength)
- JUNO +2% (presents data from the TRANSCEND trial of JCAR017 in relapsed and refractory aggressive B cell non-Hodgkin lymphoma)
- HZNP +2% (Health Canada has issued a Notice of Compliance for PROCYSBI)
- CRAY +1.9% (receives contract from New Zealand's National Institute of Water and Atmospheric Research worth $18 mln)
Analyst comments:
- CS +3.7% (upgraded to Buy from Hold at Deutsche Bank )
- AKS +2.8% (upgraded to Buy from Neutral at Longbow)
- X +2.3% (upgraded to Buy from Neutral at Longbow)
- NUE +1.1% (upgraded to Buy from Neutral at Longbow)
- AAPL +1.1% (target raised to $180 at Maxim Group)
- BIIB +1.1% (upgraded to Neutral from Sell at UBS)
- AGCO +1% (upgraded to Neutral from Underperform at BofA/Merrill)
- CNHI +0.9% (upgraded to Buy from Neutral at BofA/Merrill)